Comparative Pharmacology
Head-to-head clinical analysis: GENOPTIC versus NETROMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOPTIC versus NETROMYCIN.
GENOPTIC vs NETROMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Netromycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in bacteria.
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
4-6 mg/kg IV once daily for serious infections; 1.5-2 mg/kg IV every 8 hours for gram-negative infections. Administered as intravenous infusion over 30-60 minutes.
None Documented
None Documented
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
Terminal elimination half-life is 2-3 hours in adults with normal renal function, but may extend to 24-48 hours in patients with impaired renal function.
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Renal excretion of unchanged drug accounts for 80-90% of elimination via glomerular filtration; biliary/fecal elimination is minimal (<5%).
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic